Internal Medicine, Cardiovascular Disease · Philadelphia, PA
NPI
1245316058
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3509 N Broad St
Philadelphia, PA, 19140
Phone (215) 707-8484
Groups this clinician bills Medicare through
Medicare paid, 2024
$44K
546 services
Medicare patients, 2024
149
Average age 72
Drug cost, 2024
$10.7M
1,626 prescriptions
Company payments, 2025
$156K
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul Forfia was code 99215 (office e&m - established), 112 times for 76 patients. In total Paul Forfia billed 546 services in 16 codes, and Medicare paid $44K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-04-16.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 112 | 76 | $114.22 | $13K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 107 | 78 | $25.40 | $2,718 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 93 | 67 | $13.36 | $1,242 |
| 99291 Critical Care E&M | Facility | 60 | 22 | $171.99 | $10K |
| 99233 Hospital E&M - Subsequent | Facility | 48 | 19 | $96.07 | $4,612 |
| 99232 Hospital E&M - Subsequent | Facility | 35 | 20 | $63.76 | $2,232 |
| 99205 Office E&M - New | Facility | 35 | 35 | $147.38 | $5,158 |
| 93451 Percutaneous Transcatheterization | Facility | 15 | 14 | $104.92 | $1,574 |
| 99222 Hospital E&M - Initial | Facility | 11 | 11 | $102.51 | $1,128 |
By year: 2022 $35K for 343 services; 2023 $36K for 333 services; 2024 $44K for 546 services.
Medicare prescription drug claims, 2024
In 2024, the drug Paul Forfia prescribed most often to Medicare patients was Adempas (Riociguat), with 300 prescriptions and refills. In total Paul Forfia wrote 1,626 Medicare prescriptions that cost $10.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Adempas Riociguat | 300 | 300 | 29 | $4.1M |
| Opsumit Macitentan | 179 | 179 | 21 | $2.3M |
| Sildenafil Citrate Generic | 152 | 198 | 21 | $47K |
| Furosemide Generic | 137 | 274 | 40 | $655 |
| Tyvaso Dpi Treprostinil | 104 | 104 | 15 | $2.5M |
| Bumetanide Generic | 86 | 193 | 25 | $4,467 |
| Ambrisentan Generic | 73 | 73 | Under 11 | $149K |
| Tadalafil Generic | 58 | 58 | Under 11 | $33K |
| Potassium Chloride Generic | 51 | 101 | Under 11 | $940 |
| Orenitram Er Treprostinil Diolamine | 48 | 48 | Under 11 | $606K |
| Eliquis Apixaban | 46 | 72 | 11 | $43K |
| Spironolactone Generic | 42 | 98 | 11 | $273 |
| Losartan Potassium Generic | 29 | 41 | Under 11 | $231 |
| Bosentan Generic | 26 | 26 | Under 11 | $70K |
| Digoxin Generic | 20 | 22 | Under 11 | $202 |
Brand drugs: 813 claims; generic drugs: 813 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul Forfia $156K ($156K in general payments such as food, travel and fees) from 7 companies. The largest payer was United Therapeutics Corporation with $68K.
| Company | Payments | Amount |
|---|---|---|
| United Therapeutics Corporation UTHR | 84 | $68K |
| Actelion Pharmaceuticals US, Inc. JNJ | 52 | $60K |
| Merck Sharp & Dohme LLC MRK | 29 | $25K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $3,044 |
| Scpharmaceuticals Inc. SCPH | 1 | $90.16 |
| Sandoz Inc. SDZ.SW | 1 | $28.62 |
| Johnson & Johnson Health Care Systems Inc. JNJ | 1 | $15.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.